Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron (Nasdaq: GERN) granted inducement stock options effective March 17, 2026, to six newly hired employees totaling 956,250 shares.
The options carry an exercise price of $1.62 (the closing price on the grant date), a 10-year term, and vest over four years (12.5% at six months, remainder monthly over 42 months), granted under Nasdaq Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported RYTELO (imetelstat) net product revenue of $48.0M in Q4 2025 and $183.6M for full year 2025, with year-end cash and marketable securities of $401.1M. Total operating expenses for 2025 were $254.7M. For 2026 the company reiterated guidance of $220M–$240M RYTELO revenue and $230M–$240M operating expenses and expects current cash plus anticipated net revenues to fund operations.
Geron noted a 9% quarterly demand increase, ~1,300 ordering accounts, ongoing investigator and real-world trials with initial data expected H2 2026, and a workforce reduction that produced $17.0M of restructuring charges.
Geron (Nasdaq: GERN) said members of management will present at three investor events in early March 2026: TD Cowen (fireside chat) on March 2, 2026 in Boston, Barclays (fireside chat) on March 10, 2026 in Miami, and Leerink Partners in-person meetings on March 11, 2026 in Miami.
A live and archived audio webcast of each fireside chat will be available via the Investors & Media section of Geron’s website at www.geron.com.
Geron (Nasdaq: GERN) granted inducement stock options effective Feb 17, 2026, to one newly hired employee for an aggregate of 742,500 shares.
The options carry an exercise price of $1.80 per share (closing price on grant date), a 10-year term, and vest over four years with 12.5% vesting at six months and the remainder in equal monthly installments over 42 months, subject to continued employment and plan terms.
Geron (Nasdaq: GERN) will release fourth quarter and full year 2025 financial results and business highlights before market open on Wednesday, February 25, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time.
Live and archived audio will be available from the Investors and Media section of the company's website at www.geron.com.
Geron (Nasdaq: GERN) provided 2026 financial guidance forecasting RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million. The company expects top-line growth driven by focused U.S. commercial efforts and stronger second-half performance, plus year‑over‑year operating expense reduction following a strategic restructuring. Geron also noted expanded clinical evidence for RYTELO in LR‑MDS and amended its 5‑year senior secured term loan to extend the outside date for Tranche B ($75M) and Tranche C ($50M) to July 30, 2026.
Geron (Nasdaq: GERN) announced an inducement equity grant effective Dec 17, 2025 for a newly hired employee: 320,000 stock options with an $1.34 exercise price (equal to the grant-date close).
The options have a 10-year term and vest over 4 years (12.5% at the six-month anniversary, then remaining shares vesting in equal monthly whole-share installments over the next 42 months). Grants were approved under Nasdaq Listing Rule 5635(c)(4) and the company’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) announced a strategic restructuring on Dec. 11, 2025 to sharpen its U.S. RYTELO commercial strategy and prioritize clinical development, including the Phase 3 IMpactMF trial. The plan targets an approximately one-third reduction of the company’s ~260-employee workforce and is expected to be substantially complete in Q1 2026.
Management expects initial projected full-year 2026 operating expenses to be lower than projected 2025 expenses, with savings beginning in Q1 2026. Geron will incur restructuring charges, primarily cash-based, and said it will disclose additional details in a Form 8-K filed with the SEC.
Geron (Nasdaq: GERN) presented pooled and long-term data at ASH 2025 on RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis. Post-hoc pooled IMerge analyses linked early treatment-emergent neutropenia and thrombocytopenia in the first two cycles to greater hemoglobin increases and higher rates of red blood cell transfusion independence.
At a median follow-up of 45 months, IMerge showed a favorable trend in overall survival, PFS, and time to AML progression versus placebo though the trial was not powered for OS. Additional ASH data include dose-dependent cytokine reductions in IMbark and a recommended combinational dose of 8.9 mg/kg from IMproveMF.
Geron (Nasdaq: GERN) reported Q3 2025 results and business highlights on November 5, 2025. RYTELO net product revenue was $47.2M in Q3 2025 versus $28.2M in Q3 2024. The company completed enrollment of 320 patients in the Phase 3 IMpactMF trial and expects an interim overall survival analysis in 2H 2026 and a final analysis in 2H 2028. Cash and marketable securities were approximately $421.5M at September 30, 2025.
Q3 net loss narrowed to $18.4M ($0.03/share) from $26.4M a year earlier. 2025 operating expense guidance was revised lower to $250–$260M. Leadership additions include a new Chief Commercial Officer and other executive hires. The company will present data at ASH 2025 and hosted a conference call on November 5, 2025.